|
|
|
|
| MPR242 | 前列腺癌组织芯片，附病理分级，TNM和临床分期，6例/24点，替代T196b | | 点 数 | 24 | 例 数 | 6 | | 行 数 | 4 | 列 数 | 6 | | 点直径(mm) | 1.5 | 厚度(µm) | 5.0 | | 组织阵列类型 | 石蜡包埋 | 种 属 | 人类 | | QA/QC | H&E and IHC confirmed | | Applications | Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page. | | Notes | 1.Please keep the slides at 4 ℃ after receiving, and make experiment within 3 months will be better. 2.Bake the slides for 30 minutes at 60℃ before the experiment; 3.Please choose a gentle repair method to avoid tissue detachment. |
|
|
| |
|
Legend:
|
|
Malignant (II) Malignant (IIA) Malignant (III) |
|
|
|
| |
| Pos | No | Age | Sex | Organ_Anatomic_Site | Pathology_diagnosis | Grade | TNM | Stage | Type | isBackUp |
| A1 | 1 | 74 | M | Prostate | Adenocarcinoma | 3 | T2N0M0 | II | Malignant | N |
| A2 | 2 | 64 | M | Prostate | Adenocarcinoma | 3 | T3N0M0 | III | Malignant | N |
| A3 | 3 | 73 | M | Prostate | Adenocarcinoma | 4 | T3N0M0 | III | Malignant | N |
| A4 | 4 | 74 | M | Prostate | Adenocarcinoma | 3 | T2N0M0 | II | Malignant | N |
| A5 | 5 | 64 | M | Prostate | Adenocarcinoma | 3 | T3N0M0 | III | Malignant | N |
| A6 | 6 | 73 | M | Prostate | Adenocarcinoma | 4 | T3N0M0 | III | Malignant | N |
| B1 | 7 | 65 | M | Prostate | Adenocarcinoma | 4 | T2aN0M0 | IIA | Malignant | N |
| B2 | 8 | 60 | M | Prostate | Adenocarcinoma | 4 | T3N0M0 | III | Malignant | N |
| B3 | 9 | 69 | M | Prostate | Adenocarcinoma | 4 | T2aN0M0 | IIA | Malignant | N |
| B4 | 10 | 65 | M | Prostate | Adenocarcinoma | 4 | T2aN0M0 | IIA | Malignant | N |
| B5 | 11 | 60 | M | Prostate | Adenocarcinoma | 4 | T3N0M0 | III | Malignant | N |
| B6 | 12 | 69 | M | Prostate | Adenocarcinoma | 4 | T2aN0M0 | IIA | Malignant | N |
| C1 | 13 | 74 | M | Prostate | Adenocarcinoma | 3 | T2N0M0 | II | Malignant | N |
| C2 | 14 | 64 | M | Prostate | Adenocarcinoma | 3 | T3N0M0 | III | Malignant | N |
| C3 | 15 | 73 | M | Prostate | Adenocarcinoma | 4 | T3N0M0 | III | Malignant | N |
| C4 | 16 | 74 | M | Prostate | Adenocarcinoma | 3 | T2N0M0 | II | Malignant | N |
| C5 | 17 | 64 | M | Prostate | Adenocarcinoma | 3 | T3N0M0 | III | Malignant | N |
| C6 | 18 | 73 | M | Prostate | Adenocarcinoma | 4 | T3N0M0 | III | Malignant | N |
| D1 | 19 | 65 | M | Prostate | Adenocarcinoma | 4 | T2aN0M0 | IIA | Malignant | N |
| D2 | 20 | 60 | M | Prostate | Adenocarcinoma | 4 | T3N0M0 | III | Malignant | N |
| D3 | 21 | 69 | M | Prostate | Adenocarcinoma | 4 | T2aN0M0 | IIA | Malignant | N |
| D4 | 22 | 65 | M | Prostate | Adenocarcinoma | 4 | T2aN0M0 | IIA | Malignant | N |
| D5 | 23 | 60 | M | Prostate | Adenocarcinoma | 4 | T3N0M0 | III | Malignant | N |
| D6 | 24 | 69 | M | Prostate | Adenocarcinoma | 4 | T2aN0M0 | IIA | Malignant | N | | Tissue Marker |
|
|
